Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
Total Valuation
Janux Therapeutics Inc has a market cap or net worth of $1.51B. The enterprise value is $2.04B.
Market Cap$1.51B
Enterprise Value$2.04B
Share Statistics
Janux Therapeutics Inc has 59,168,490 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,168,490
Owned by Insiders55.01%
Owned by Institutions<0.01%
Financial Efficiency
Janux Therapeutics Inc’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -9.45%.
Return on Equity (ROE)-0.07
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-9.45%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee130.72K
Profits Per Employee-851.78K
Employee Count81
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Janux Therapeutics Inc is -41.71. Janux Therapeutics Inc’s PEG ratio is 13.76.
PE Ratio-41.71
PS Ratio0.00
PB Ratio2.81
Price to Fair Value2.81
Price to FCF-65.15
Price to Operating Cash Flow-65.68
PEG Ratio13.76
Income Statement
In the last 12 months, Janux Therapeutics Inc had revenue of 10.59M and earned -68.99M in profits. Earnings per share was -1.28.
Revenue10.59M
Gross Profit10.59M
Operating Income-98.85M
Pretax Income-68.99M
Net Income-68.99M
EBITDA-98.85M
Earnings Per Share (EPS)-1.28
Cash Flow
In the last 12 months, operating cash flow was -43.81M and capital expenditures -359.00K, giving a free cash flow of -44.17M billion.
Operating Cash Flow-43.81M
Free Cash Flow-44.17M
Free Cash Flow per Share-0.75
Dividends & Yields
Janux Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.21
52-Week Price Change-49.23%
50-Day Moving Average29.69
200-Day Moving Average42.86
Relative Strength Index (RSI)39.10
Average Volume (3m)931.31K
Important Dates
Janux Therapeutics Inc upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Janux Therapeutics Inc as a current ratio of 59.21, with Debt / Equity ratio of 2.25%
Current Ratio59.21
Quick Ratio59.21
Debt to Market Cap<0.01
Net Debt to EBITDA4.12
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Janux Therapeutics Inc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Janux Therapeutics Inc EV to EBITDA ratio is -24.99, with an EV/FCF ratio of -55.92.
EV to Sales233.31
EV to EBITDA-24.99
EV to Free Cash Flow-55.92
EV to Operating Cash Flow-56.38
Balance Sheet
Janux Therapeutics Inc has $1.03B in cash and marketable securities with $25.30M in debt, giving a net cash position of -$1.00B billion.
Cash & Marketable Securities$1.03B
Total Debt$25.30M
Net Cash-$1.00B
Net Cash Per Share-$16.94
Tangible Book Value Per Share$19.03
Margins
Gross margin is 90.20%, with operating margin of -933.58%, and net profit margin of -651.62%.
Gross Margin90.20%
Operating Margin-933.58%
Pretax Margin-651.62%
Net Profit Margin-651.62%
EBITDA Margin-933.58%
EBIT Margin-933.58%
Analyst Forecast
The average price target for Janux Therapeutics Inc is $93.13, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$93.13
Price Target Upside262.37% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast30.99%
EPS Growth Forecast4.61%